

28 December 2023

## Osteopore signs Bridging Loan agreement

Osteopore Limited (**ASX: OSX; Osteopore or Company**) a global regenerative medicine company founded in Singapore and listed in Australia, is pleased to advise that the Company has entered into a bridging loan agreement with Advance Opportunities Fund I (**Lender**)(**AOF I**), for a bridging loan of S\$1,000,000 to the Company (**Bridging Loan**). AOF I is an open-ended fund incorporated as an exempted company with limited liability in the Cayman Islands in 2016.

The Company intends to utilise the Bridging Loan funds for working capital and general corporate purposes.

The key terms of the Bridging Loan include:

- A term of 90 calendar days from the date of disbursement. It can be extended on a month-to-month basis for a maximum period of two (2) calendar months.
- Upfront interest payable of S\$90,000 and an interest rate of 3% per month for the first 3 months, 4% per month for the fourth month, and 5% per month on the fifth month and thereafter. Default interest shall accrue on the amount outstanding on a daily basis at the rate of 8% per month up to and including the date on which the Lender receives full payment of the outstanding amount, together with the accrued default interest.
- Administrative fee of S\$60,000 payable to Advance Capital Partners Pte Ltd (**ACP**). ACP is a private limited company registered in Singapore and has been appointed by the Lender as its authorised representative to coordinate and manage the Bridging Loan.
- Legal costs and expenses incurred by the Lender in connection with the Bridging Loan amounting to S\$15,000 shall be paid by the Company.
- The Bridging Loan is secured with the issued and paid-up capital of the Company's wholly owned subsidiary, Osteopore International Pte Ltd, duly incorporated in Singapore.



- Except for any subscriptions which will result in a post dilution stake of less than 10%, the Company agrees:
  - a) to grant the Lender a tag-along right to participate in any proposed fund raising exercise to be undertaken by the Company during the loan tenure, and
  - b) that any subsequent subscription monies from any proposed fund raising exercise, a portion of the subscription monies received shall be reserved and utilised for the repayment of the Bridging Loan.

The Bridging Loan agreement contains customary events of default including the following material events of default:

- The delisting of the Company's shares on the ASX or a suspension of trading of such shares on the ASX for a period of seven (7) consecutive business days or more save for suspension caused by administrative or technical error not due to the Lender or trading halts made at the request of the Lender for corporate announcements or circular(s) pending clearance by the ASX or other regulatory or governmental bodies; and
- Any change in the majority of the existing members of the board of directors in the Company without first obtaining the prior written consent of the Lender.

**ENDS**

*This announcement dated 28 December 2023 has been authorised for release to the ASX by the Board of Osteopore Limited.*

For more information, please contact:

**Mark Leong**

Executive Chairman

Osteopore Limited

T: +65 9011 7009

E: [mark\\_leong@osteopore.com](mailto:mark_leong@osteopore.com)

**Isaac Stewart**

Media & Investor Relations

Cannings Purple

T: +61 423 306 795

E: [istewart@canningspurple.com.au](mailto:istewart@canningspurple.com.au)



### About Osteopore Limited

Osteopore Ltd is an Australian-Singaporean medical technology company aiming to commercialise products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

### Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are or may be, forward-looking statements.

Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Depending on several factors, actual results may differ materially from those expressed or implied by these forward-looking statements.

